Using fosfomycin in the treatment of acute uncomplicated cystitis. An ob-gyn perspective

Lisitsina O.I.

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia
Urinary tract infections (UTIs) are among the most common bacterial infections worldwide. A significant number (up to 60%) of consultations with a specialist is associated with acute or recurrent cystitis. 20-25% of women suffer from acute cystitis over the life course, one in three of them has a disease relapse within a year. The disease leads to the patients’ reduced quality of life, adversely affecting social and labour activity. The goal of treating an uncomplicated UTIs is to eliminate the symptoms, eradicate the pathogen, prevent relapse, prevent complications and improve the quality of life of the patient. According to the Russian clinical recommendations for urology, fosfomycin trometamol, furazidin potassium salt with magnesium carbonate and nitrofurantoin are the drugs of choice. Given the high efficacy and safety of the fosfomycin oral form, as well as the single-dose antibacterial drug regimen, this medical agent has several undeniable advantages: it is most convenient for the patient (which contributes to its compliance), reduces the cost of treatment, and decreases the possibility of side effects compared with longer antibiotics regimen.


acute uncomplicated cystitis
urinary tract infections


  1. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 2011; 52(5): e103-20.
  2. Mannucci C., Dante G., Miroddi M., Facchinetti F., D’Anna R., Santamaria A. et al. Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin. J. Matern. Neonatal Med. 2019;32(1): 125-8.
  3. Leeper C., Lutzkanin A. Infections during pregnancy. Prim. Care. 2018; 45(3): 567-86.
  4. Зайцев А.В., Касян Г.Р., Спивак Л.Г. Цистит. В кн.: Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю., ред. Урология. Российские клинические рекомендации. М.: Медфорум; 2017: 501-18. [Zaitsev A.V., Kasyan G.R., Spivak L.G. Cystitis. In the book: Alyaev Yu.G., Glybochko P.V., Pushkar D.Yu., ed. Urology. Russian clinical guidelines. M .: Medforum; 2017: 501-18. (in Russian)]
  5. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. North Am. 2014; 28(1): 1-13.
  6. Балушкина А.А., Кан Н.Е., Тютюнник В.Л. Современный взгляд на терапию инфекций мочевыводящих путей у беременных. РМЖ. Медицинское обозрение. 2018; 2(8-1): 37-40. [Balushkina A.A., Kan N.E., Tyutyunnik V.L. A modern view on the treatment of urinary tract infections in pregnant women. Breast cancer Medical Review. 2018; 2 (8-1): 37-40.(in Russian)]
  7. Сухих Г.Т., ред. Беременность и роды при заболеваниях мочевыводящих органов. М.; 2009. [Sukhikh G.T., ed. Pregnancy and childbirth in diseases of the urinary organs. M .; 2009. (in Russian)]
  8. Рафальский В.В. Антибиотикорезистентность возбудителей неосложненных инфекций мочевых путей в Российской Федерации. Вестник урологии. 2018; 6(3): 50-6. [Rafalsky V.V. Antibiotic resistance of pathogens of uncomplicated urinary tract infections in the Russian Federation. Herald of Urology. 2018; 6 (3): 50-6. (in Russian)]
  9. Chlabicz S., Leszczynska K., Lukas W., Gualco L., Schito G., Naber K.G. Uncomplicated lower urinary tract infections in females--clinical aspects, aetiology and antimicrobial resistance epidemiology. Results of the ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study in Poland and their implications for empiric therapy. Przegl. Epidemiol. 2011; 65(2):345-51.
  10. Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Шевелев А.Н., Гринев А.В., Перепанова Т.С., Козлов Р.С., Коган М.И. Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС» (2010–2011). Клиническая микробиология и антимикробная химиотерапия. 2012; 14(4): 280-302. [Palagin I.S.,Sukhorukova M.V., Dekhnich A.V., Eidelstein M.V., Shevelev A.N., Grinev A.V., Perepanova TS, Kozlov R.S., Kogan M. .AND. The current state of antibiotic resistance of causative agents of community-acquired urinary tract infections in Russia: the results of the DARMIS study (2010–2011). Clinical microbiology and antimicrobial chemotherapy. 2012; 14 (4): 280-302. (in Russian)]
  11. Каптильный В.А. Острый цистит в практике акушера-гинеколога. Медицинский совет. 2018; 13: 114-23. [Kaptilny V.A. Acute cystitis in the practice of an obstetrician-gynecologist. Medical advice. 2018; 13: 114-23. (in Russian)]
  12. Bader M.S., Loeb M., Brooks A.A. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad. Med. 2017; 129(2): 242-58.
  13. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., Athanasiou S. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 2010; 65(9): 1862-77.
  14. Колонтарев К.Б., Зайцев А.В., Пушкарь Д.Ю. Сравнительный анализ анти- бактериальной терапии острого цистита. Урология. 2013; 3: 112-22. [Kolontarev KB, Zaitsev AV, Pushkar D.Yu. Comparative analysis of anti-bacterial treatment of acute cystitis. Urology. 2013; 3: 112-22. (in Russian)]
  15. Chen Y.T., Ahmad Murad K., Ng L.S., Seah J.T., Park J.J., Tan T.Y. In vitro efficacy of six alternative antibiotics against multidrug resistant escherichia coli and Klebsiella pneumoniae from urinary tract infections. Ann. Acad. Med. Singapore. 2016; 45(6): 245-50.
  16. Aris P., Boroumand M.A., Rahbar M., Douraghi M. The activity of fosfomycin against extended-spectrum beta-lactamase-producing isolates of enterobacteriaceae recovered from urinary tract infections: a single-center study over a period of 12 years. Microb. Drug Resist. 2017; 24(5): 607-12.
  17. Yu H.S., Hwang E.C., Jung S.I., Kang T.W., Kwon D.D., Chung H.S. et al. Antimicrobial susceptibilities of urinary extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin in health care associated urinary tract infection. Eur. Urol. 2015; 14(2, Suppl.): e249.
  18. Mezzatesta M.L., La Rosa G., Maugeri G., Zingali T., Caio C., Novelli A., Stefani S. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens. Int. J. Antimicrob. Agents. 2017;49(6): 763-6.
  19. Fosfomycin for UTIs. Drug Ther. Bull. 2016; 54(10): 114-7.
  20. Яровой С.К. Место фосфомицина в медикаментозной терапии заболеваний мочеполовой системы. Экспериментальная и клиническая урология. 2013; 4: 115-20. [Yarovoy S.K. Place fosfomycin in drug therapy of the urinary system. Experimental and clinical urology. 2013; 4: 115-20. (in Russian)]

Received 15.02.2019

Accepted 22.02.2019

About the Authors

Lisitsyna, Olga I., intern of General Surgery, National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov, Ministry of Healthcare of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79167195406. E-mail:

For citations: Lisitsyna O. I. Using fosfomycin in the treatment of acute uncomplicated cystitis. An ob-gyn perspective. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2019; (2): 165-9. (in Russian)

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.